Syntex "cost reduction program"
In response to "disappointing results" in the first two months of FY 1993, Syntex announced Oct. 21 that it will undertake a restructuring of "some" marketing and administrative organizations, the elimination of "a number of positions" and "reprioritizing [of] some" R&D activities. Syntex said it plans to consolidate "some production facilities at a later date." Details of the plan are sketchy: "no final decisions have yet been made regarding the number of positions and programs to be eliminated ...nor [has the company] definitively determined the financial impact of such actions," Syntex explained. A spokesperson said the program will be completed "within the next couple of months." Syntex' Toradol analgesics line is not performing up to expectations while the clock is running out on the firm's naproxen patent.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth